Pharmaceuticals & Therapeutics

A group known for challenging pandemic rules will now advise on US vaccine policy. Can it rebuild trust, or will it deepen the medical divide?

A new partnership between a Chinese biotech and a Brazilian public institute aims to slash the $500k cost of CAR-T therapy, making it accessible to all.

My Derma Dream's MyoGlow promises a surgery-free arm lift. We investigate the science, the marketing, and the guarantee fine print consumers must see.

A new company is selling franchises to doctors and pharmacists, promising to cut out insurers and restore local care. But can this bold model survive the system?

A new natural suppository aims to break the cycle of recurrent yeast infections by supporting the vaginal microbiome, offering hope to millions of women.

Florida's Dunamis Premium Spirits is making waves, targeting the global cruise market with its award-winning, mission-driven brands. Here's how.

With Nuvaxovid set for a 2026 rollout, Sanofi aims to address vaccine hesitancy and expand choices as Canada continues to battle the virus.

With a personal family connection to type 1 diabetes and a £100M war chest, Anastasia Bukhman joins the T1D Fund's board to speed up research.

A new non-invasive therapy using ultrasound to activate a cancer-targeting drug enters a crucial Phase 2b trial, offering new hope for glioblastoma patients.

1 Hotel Hanalei Bay blends cutting-edge biohacking with the raw power of nature, aiming to redefine luxury wellness. Is this the future of health travel?

With its European trial launch, Kainova's DT-7012 aims to disarm cancer's bodyguards, offering new hope for patients with advanced solid tumors.

Treating over 100,000 patients in two years, a novel gel therapy is leading a paradigm shift in interventional dry eye management. Here's how.

Eli Lilly's new once-daily oral GLP-1, Foundayo, is now on telehealth platform Ro, offering a convenient, needle-free alternative to injectable drugs.

Following a massive stock surge, Forte Biosciences is raising $150M. The funds are crucial for a pivotal year of clinical trials for its autoimmune drug.

Absci will showcase its generative AI drug discovery platform at a key healthcare conference, highlighting its ambitious pipeline for hair loss and endometriosis.

With its future riding on a pivotal trial for avexitide, Amylyx's upcoming conference presentation offers a crucial look into its post-ALS strategy.

Altruist Biologics secures a landmark license for China's largest bioreactor facility, signaling a major shift in the global biopharmaceutical supply chain.

With a $137M war chest, Sidewinder Therapeutics is advancing a new class of ultra-precise cancer drugs aimed at tumors that have long evaded treatment.

Blue Faery recognizes two doctors whose groundbreaking research in immunotherapy and targeted drugs has created new standards of care for liver cancer patients.

The dermatologist-founded brand is expanding access to clinical-grade treatments for underserved skin concerns, signaling a major shift in the industry.